Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04132817 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04132817 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 12 participants.
The verdict
NCT04132817, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerability, pharmacodynamic activity and efficacy of targeting multiple, distinct combination regimens that modulate several immune and non-immune mechanisms by escalating the number of therapies administered.
Interventions
- BIOLOGICAL Nivolumab
- DRUG Nab-paclitaxel
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04132817
The ClinicalTrials.gov registry entry for NCT04132817 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT04132817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04132817 about?
NCT04132817 is a clinical study titled "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread". The hypothesis of the CA048-001 Phase 1 clinical trial is targeting multiple mechanisms involved in generating and maintaining antitumor immune response will lead to a tolerable and robust anti-tumor response. This study utilizes an innovative clinical trial design to determine the safety, tolerabil...
What is the current status of trial NCT04132817?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-09-22. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT04132817?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nab-paclitaxel (DRUG), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04132817?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.